Document:

Exhibit

Exhibit 10.8
SUBORDINATION OF ADVISORY FEES 
The undersigned CARTER VALIDUS ADVISORS II, LLC, a Delaware limited liability company, (the “Advisor”), which provides advisory services with respect to certain investment opportunities on behalf of CARTER VALIDUS MISSION CRITICAL REIT II, INC., a Maryland corporation (“Borrower”) and CARTER VALIDUS OPERATING PARTNERSHIP II, LP, a Delaware limited partnership (“CVOP II”), acknowledges that this Subordination of Advisory Fees (this “Agreement”) is being executed and delivered to satisfy a certain obligation of Borrower set forth in that certain Loan Agreement dated as of even date herewith (herein, together with all supplements, amendments and restatements thereto, referred to as the “Term Loan Agreement”) by and among Borrower, KEYBANK NATIONAL ASSOCIATION, a national banking association (“KeyBank”), individually and as administrative agent (“Agent”) for itself and the other lending institutions from time to time party to the Loan Agreement (collectively, the “Lenders”).  Any capitalized terms used herein but not defined herein shall have the same meanings as are ascribed to them in the Loan Agreement.
CVOP II, Borrower and Advisor hereby agree with Agent as follows:
1.Advisor acknowledges and understands that this Agreement is being executed and delivered to satisfy a certain obligation of Borrower pursuant to the Loan Agreement.
2.    For purposes hereof, “Advisory Agreement” shall mean that certain Amended and Restated Advisory Agreement, dated June 10, 2014, by and among Advisor, CVOP II and Borrower, and as may be amended, supplemented or otherwise modified from time to time in accordance with the terms of this Agreement.
3.    Any rights and claims of Advisor against CVOP II and/or Borrower under the Advisory Agreement for the payment of compensation are and shall be subject and subordinate in all respects to (i) the Loan Documents and the rights and claims of the Agent and the Lenders thereunder, and (ii) any and all modifications, amendments, renewals, restatements or substitutions of the Loan Documents; provided, however, Advisor shall be entitled to receive, on a monthly basis, its fees for services rendered in accordance with the Advisory Agreement pursuant to the payment procedures outlined therein.  This Section 3 shall be self-operative and no further instrument of subordination shall be required.  If requested, however, CVOP II, Borrower or Advisor shall execute and deliver such further instruments as the Agent may deem reasonably necessary to effectuate this subordination.
4.    In furtherance of Section 3 above, Advisor hereby subordinates any and all right of compensation, indemnification and reimbursement of fees and expenses under the Advisory Agreement to all of the Obligations, and agrees with Agent that upon the occurrence and during the continuance of an “Event of Default” (as defined in the Loan Agreement) (a) Advisor shall not demand or accept any such payment under or in respect of the Advisory Agreement, and (b) Advisor shall not take any action to obtain any interest in any of the security described in and encumbered by the Loan Documents, if any, because of any such obligation; provided, however, that, if Agent 

so requests, such compensation, indemnification or reimbursement shall be collected, enforced and received by Advisor as trustee for Agent and be paid over to Agent on account of the Obligations.  
5.    This Agreement shall inure to the benefit of the Agent, the Lenders and their respective successors and assigns.  In the event of any inconsistency or conflict with the provisions of this Agreement and the provisions of the Advisory Agreement, the provisions of this Agreement shall control.
6.    Advisor agrees that it shall not change, amend, modify or terminate the Advisory Agreement to impose additional obligations on Borrower or CVOP II, to alter the timing of payments due thereunder or in any other material respect without the Agent’s prior written approval in each instance, which approval shall not be unreasonably withheld.  If Advisor does so amend, modify or terminate the Advisory Agreement in violation of this Section 6, such amendment, modification or termination shall be void ab initio. 
7.    This Agreement shall pursuant to Section 5-1401 of the New York General Obligations Law be governed by, and construed in accordance with, the internal laws of the State of New York.
8.    Without limiting the generality of any other provisions contained herein or in the other Loan Documents, no failure on the part of the Agent or the Lenders to exercise, and no delay in exercising, any right hereunder or under any of the other Loan Documents shall operate as a waiver thereof, nor shall any single or partial exercise of any right preclude any other or further exercise thereof or the exercise of any other right.  The rights and remedies of the Agent and the Lenders provided herein and in the other Loan Documents are cumulative and are in addition to, and are not exclusive of, any rights or remedies provided by law or in equity.
9.    Advisor represents and warrants to the Agent that as of the date hereof (i) the Advisory Agreement is in full force and effect and (except as reflected in copies delivered to Agent) has not been amended, modified, assigned, terminated or supplemented, (ii) Advisor is not in default under the provisions of the Advisory Agreement and there is no condition which, with the giving of notice and/or the lapse of time, would constitute such a default and (iii) to the best of Advisor’s knowledge, neither CVOP II nor Borrower is in default under the provisions of the Advisory Agreement and there is no condition which, with the giving of notice and/or the lapse of time, would constitute such a default.
10.    This Agreement may not be amended, modified, terminated or supplemented without the written approval of each of Advisor, CVOP II, Borrower and the Agent.
11.    This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. 
 [Signatures Begin on the Following Page]

2

IN WITNESS WHEREOF, the Advisor has executed and delivered this Agreement as of the 7th day of August, 2019.

ADVISOR:
CARTER VALIDUS ADVISORS II, LLC, a Delaware limited liability company
By:/s/ Kay C. Neely
Name: Kay C. Neely
Title: Chief Financial Officer and Treasurer

[Signatures Continued On Next Page]

Signature Page to Subordination of Advisory Fees

AGREED AND CONSENTED TO:
CVOP II:
CARTER VALIDUS OPERATING PARTNERSHIP II, LP, a Delaware limited partnership
		
	By:
	Carter Validus Mission Critical REIT II, Inc., a Maryland corporation, its general partner

		
	By:
	/s/ Kay C. Neely

Name: Kay C. Neely
Title:   Chief Financial Officer and Treasurer
(SEAL)

[Signatures Continued On Next Page]

Signature Page to Subordination of Advisory Fees

AGREED AND CONSENTED TO:
BORROWER:
CARTER VALIDUS MISSION CRITICAL REIT II, INC., a Maryland corporation
By:/s/ Kay C. Neely 
Name: Kay C. Neely
Title:   Chief Financial Officer and Treasurer
(SEAL)

[Signatures Continued On Next Page]

Signature Page to Subordination of Advisory Fees

AGREED AND CONSENTED TO:
AGENT:
KEYBANK NATIONAL ASSOCIATION, as Agent
By: /s/ Kristin Centracchio 
Name: Kristin Centracchio 
Title:   Vice President

Signature Page to Subordination of Advisory FeesEX-10.1

 Exhibit 10.1 

[***] = Certain information, marked by brackets, has been excluded from this exhibit because such information (i) is not material and
(ii) would likely cause competitive harm to the registrant if publicly disclosed. 
 CONFIDENTIAL 

Execution Version 

AMENDMENT NO. 2 
 TO

 AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT 

THIS AMENDMENT NO. 2 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment”) is made as of June 3,
2019 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California
(“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated
Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 to Amended and Restated Exclusive (Equity) Agreement, dated as of May 3, 2018 (the
“Original Agreement,” and as amended by this Amendment, the “Agreement”). 
 RECITALS 

WHEREAS, the Parties desire to revise the definition of Biological Materials in the Original Agreement and revise certain timelines and
diligence milestones set forth in the Original Agreement, all as set forth in this Amendment; 
 WHEREAS, pursuant to
Section 19.4 of the Original Agreement, the Original Agreement may be amended in writing executed by authorized representatives of Stanford and LogicBio; and 

WHEREAS, in accordance with Section 19.4 of the Original Agreement, Stanford and LogicBio desire to amend the Agreement in the
manner provided herein. 
 AGREEMENT 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be
legally bound, Stanford and LogicBio hereby agree as follows: 
  

	 	1.	 Amendment of Agreement. 

 

	 	a.	 The Agreement is hereby amended by deleting the street address “700 Main Street” appearing in the
first paragraph of the Agreement and in Section 18.2 of the Agreement and inserting in place thereof the street address “99 Erie Street”. 

  

	 	b.	 Section 2.2 of the Agreement is hereby amended and restated as follows: 

“Biological Material” means (a) pAAV-DJ and pHelper vectors, (b) NP59
Capsid, (c) LK03 Capsid, (d) pAB269, (e) pAB270, (f) pAB288 and (g) pAB325 ((d)-(g) described in Stanford Docket 16-095), in each case to be provided by Stanford to LogicBio under this
Agreement. 

	 	c.	 Section 2.32 of the Agreement is hereby amended by: 

 

	 	i.	 deleting the words “the diagnosis, prevention or treatment of human disease via genome editing without a
nuclease” appearing in Section 2.32(A)(1) therein and inserting in place thereof the words “the diagnosis, prevention or treatment of human disease, including, for clarity, hemophilia A and
Alpha-1 antitrypsin disease, via genome editing without a nuclease”. 

  

	 	ii.	 deleting the words “[***]” appearing therein and inserting in place thereof the words
“[***]”. 

  

	 	d.	 Section 3.1(A)(2) of the Agreement is hereby amended by including the following as the final sentence of
the Agreement: “For clarity, the license is Exclusive for the GT Licensed Patents with respect to any indication that is then included within the Tissue Field of Use, regardless of whether such indication is also included within the Non-Exclusive Field of Use.” 

  

	 	e.	 Section 3.3 of the Agreement is hereby amended by deleting the words “[***]” appearing therein
and inserting in place thereof the words “[***]”. 

  

	 	f.	 Section 6.3 of the Agreement is hereby amended by deleting the words “first anniversary”
appearing therein and inserting in place thereof the words “second anniversary”. 

  

	 	g.	 Appendix C – Milestones of the Agreement is hereby amended by replacing Appendix C of the Agreement with
the Appendix A of this Amendment. 

  

	 	h.	 Appendix E – Technology of the Agreement is hereby deleted in its entirety and replaced with Appendix
B of this Amendment. 

  

	 	2.	 Payment. LogicBio will pay to Stanford a noncreditable, nonrefundable fee of Twenty Thousand Dollars
($20,000) within [***] business days of the Amendment Effective Date. 

  

	 	3.	 Continued Validity of Agreement. Except as specifically amended hereby, the Agreement shall continue in
full force and effect as originally constituted and is ratified and affirmed by the parties hereto. 

  

	 	4.	 Successors and Assigns. The terms and conditions of this Amendment shall inure to the benefit of and be
binding upon the respective successors and assigns of the parties. Nothing in this Amendment, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations or liabilities under or by reason of this Amendment, except as expressly provided in this Amendment. 

  

	 	5.	 Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the
State of California, United States of America, applicable to agreements negotiated, executed, and performed within California. 

  

	 	6.	 Electronic Copy. This parties to this Amendment agree that a copy of the original signature (including
an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. 

 [Signature Pages to Follow] 

  
 2 

 The parties execute this Amendment in duplicate originals by their duly authorized officers
or representatives. 
 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 

Signature: /s/ Mona Wan (Jun 21, 2019)     

Name: Mona Wan 
 Title:   Associate Director 

LOGICBIO THERAPEUTICS, INC. 
 Signature: /s/ Frederic
Chereau                      
 Name: Frederic
Chereau 
 Title:   Chief Executive Officer 

SIGNATURE PAGE TO AMENDMENT TO AMENDED
AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT 

 Appendix A 
  

	1.	 [***] 

	2.	 [***] 

	3.	 [***] 

	4.	 [***] 

	5.	 [***] 

	6.	 [***] 

	7.	 [***] 

	8.	 [***] 

	9.	 [***] 

	10.	 [***] 

Product 2 
  

	1.	 [***] 

	2.	 [***] 

	3.	 [***] 

	4.	 [***] 

	5.	 [***] 

	6.	 [***] 

Product 3 for [***] indication 
  

	1.	 [***] 

	2.	 [***] 

	3.	 [***] 

	4.	 [***] 

	5.	 [***] 

	6.	 [***] 

[***] Field Milestones 
  

	1.	 [***] 

	2.	 [***] 

	3.	 [***] 

	4.	 [***] 

	5.	 [***] 

	6.	 [***] 

	7.	 [***] 

	8.	 [***] 

 Appendix B 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]